Charles River Laboratories International (NYSE:CRL) Releases FY 2025 Earnings Guidance

Charles River Laboratories International (NYSE:CRL) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 9.100-9.600 for the period, compared to the consensus estimate of 9.600. The company issued revenue guidance of $3.8 billion-$3.9 billion, compared to the consensus revenue estimate of $3.9 billion. Charles River Laboratories International also updated its FY25 guidance to $9.10-$9.60 EPS.

Analyst Ratings Changes

A number of brokerages have issued reports on CRL. UBS Group reaffirmed a “neutral” rating and set a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. JPMorgan Chase & Co. dropped their price target on Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating on the stock in a research report on Monday, February 3rd. The Goldman Sachs Group dropped their price target on Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a research report on Thursday, January 23rd. William Blair cut Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. Finally, Robert W. Baird dropped their price target on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a research report on Thursday. Three investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $196.43.

Charles River Laboratories International Stock Performance

Shares of NYSE:CRL opened at $167.59 on Thursday. The firm has a market capitalization of $8.57 billion, a PE ratio of 20.99, a P/E/G ratio of 6.01 and a beta of 1.37. Charles River Laboratories International has a 12 month low of $150.79 and a 12 month high of $275.00. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. The business has a 50-day moving average of $174.02 and a two-hundred day moving average of $188.99.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. During the same quarter last year, the firm posted $2.46 earnings per share. The business’s quarterly revenue was down 1.1% on a year-over-year basis. As a group, research analysts forecast that Charles River Laboratories International will post 10.16 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).